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Quick Response Code: INTRODUCTION
Salivary duct carcinomas (SDCs) are rare and account for approximately 6% of all malignant 
salivary gland tumors. SDC are malignant, rapidly-growing aggressive tumors with a high local 
recurrence rate, and high frequency of early metastases.[7,10,14,16,18] In this report, we present a 
77-year-old man male with an isolated T11 vertebral metastasis from a primary apocrine SDC 
of the parotid gland who was adequately managed with biopsy/surgical resection followed by 
radiation therapy.
ABSTRACT
Background: e salivary duct carcinomas (SDCs) are rare, high-grade neoplasms involving major salivary 
glands. Parotid is the most frequently involved gland (85%). Apocrine phenotype (histological presence of 
decapitation secretions) and androgen reception expression define SDC. e clinical course of these tumors is 
characterized by aggressive local behavior with extraglandular extension, high recurrence rates, early metastases, 
and poor prognoses. Despite aggressive surgical/radiation therapy management, the rates of locoregional and 
metastatic relapses are high, and the mortality rates over 48 months approach 65%. Notably, there is no treatment 
algorithm available for managing vertebral metastases from apocrine SDC.
Case Description: An elderly male presented with MR/CT findings of an isolated T11 vertebral metastasis 
attributed to a previously treated parotid SDC. On both CT/MR, it was an osteolytic lesion and demonstrated 
spinal canal infiltration. e patient underwent surgical biopsy/decompression/resection, following which the 
lesion histopathologically proved to be a SDC. e patient was subsequently treated with 30 Gy in 10 fractions 
within 2 weeks of discharge. One-month later, the MRI confirmed adequate epidural decompression without 
recurrence, and 9 months post-operatively, patient remained disease free.
Conclusion: Isolated metastasis attributed to parotid SDC followed by radiation therapy may result in tumor 
control.
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CASE REPORT
Initial presentation of SDC
A 77-year-old male with a medical history of the left-sided 
parotid carcinoma presented with the MR/CT finding of an 
isolated metastatic T11 vertebral lesion diagnosed following 
a radical parotidectomy. e histological diagnosis was 
consistent with a SDC with apocrine differentiation. At that 
time, 3 lymph nodes were positive, and the patient, therefore, 
underwent subsequently adjuvant local radiotherapy.
Presentation with T11 metastatic SDC disease
A chest-abdomen CT scan, performed 3 months later, 
showed an increase in size of the vertebral lesion and 
highlighted spinal instability. Further, the spinal MRI 
demonstrated infiltration of the spinal canal at the T11 level 
due to the SDC (i.e., Bilsky Grade 2 epidural compression) 
[Figures 1a and b].[2] e patient underwent biopsy/surgical 
decompression/resection of the tumor utilizing a left T11 
laminectomy. At surgery, the left T11 pedicle was removed, 
followed by partial T11 corpectomy and the posterior 
application of two carbon rods from T10 to T12 [Figure 2a]. 
e postoperative spinal CT scan confirmed that the fixation 
system was accurately placed and that the spinal cord was 
sufficiently decompressed [Figures 2b and c].
Histology
e initial histological diagnosis was consistent with a SDC 
with apocrine differentiation and 3 lymph nodes were positive. 
e T11 histopathology was the same. Immunohistochemical 
stainings for gross cystic disease fluid protein-15 (GCDFP15) 
and androgen receptor (e.g.,  for the T11 biopsy material) 
were diffusely positive; while cytokeratins 8/18 were focally 
positive [Figures 3a, b, c, d and e], all remaining consistent 
with the diagnosis of a SDC.
Adjuvant radiation therapy
Subsequently, patient underwent adjuvant local radiotherapy 
and received 30 Gy in 10 fractions within 2 postoperative 
weeks. One-month post-operatively, the MRI confirmed 
adequate epidural decompression without tumor recurrence 
[Figure 2d]. Nine months later, the patient remained disease 
free [Table 1].
DISCUSSION
SDC are rare, high-grade neoplasms involving major salivary 
glands, and represent approximately 6% of all salivary gland 
cancers.[12,15] e parotid gland is the most frequent involved 
(75–85%). e peak of incidence occurs in the 6th–7th decades 
of life, and there is a male predominance. Patients present 
with enlarging parotid masses, frequently associated with VII 
cranial nerve dysfunction, plus aggressive local behavior (i.e., 
with extraglandular extension), high recurrence rates, and 
early metastases correlating with poor prognoses.[10,14,16,18]
Prognosis with surgery and radiation therapy
Although there is no specific management algorithm for the 
treatment of vertebral metastases from SDCs, those with 
single osteolytic lesions and high-grade epidural compression 
may be successfully treated with aggressive gross-total 
surgical resection followed by radiation therapy.[1,3-6,8,9,13] 
Due to the frequency of SCD’s invasion and their aggressive 
Table 1: Case report details.
Primary tumor •  Left‑sided salivary duct carcinoma 
with apocrine differentiation
Primary tumor treatment •  Radical parotidectomy+selective 
lymph nodes resection and neck 
dissection
• Adjuvant radiation therapy 
Metastasis •  Single osteolytic lesion involving 
T11 vertebral body 
Preoperative assessment • ESCC grade (Bilsky score): 2 
Treatment •  Separation surgery with 
anterior-lateral decompression 
(bilateral) laminectomy, left 
pediculectomy, and ventral 
separation
•  Radiation therapy (30 Gy in 10 
fractions) 
Immunohistochemistry • GCDFP15 + (diffusely)
• AR + (diffusely)
• Cytokeratins 8/18 + (focally)
•  NTRK/NTRK2/NTRK3 
translocations
SINS: Spinal instability neoplastic score, ESCC score: Epidural spinal cord 
compression, NSE score: Neurological stability epidural compression 
score
Figure  1: Sagittal (a) and axial (b) preoperative MRI showing 
epidural compression and circumferential vertebral involvement.
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nature, surgical treatment should include a radical/
total parotidectomy with sacrifice of the facial nerve and 
ipsilateral lymph node dissection, followed by postoperative 
chemotherapy/radiotherapy. Even with such aggressive 
management, there is a nearly 65% locoregional rate of 
metastatic relapse, and patients typically succumb from 
recurrent and/or progressive disease within 48 months.[10]
Histology
Apocrine phenotype (histological presence of decapitation 
secretions) and androgen receptor expression defines SDC 
that may metastasize to the spine (e.g., to the T11 level in this 
case) warranting surgical extirpation followed by adjuvant 
radiation therapy.[11,17]
Figure 2: Intraoperative image (a) displaying the circumferential decompression and vertebral fixation with carbon fiber system. Postoperative 
sagittal (b) and axial (c) CT scan showing the accuracy of fixation system placement. Postoperative MRI image (d) demonstrating the epidural 




Figure  3: Histological findings after vertebral lesion resection. H and E image (a: 100X, b: 200X) shows a bone infiltrating metastatic 
carcinoma with duct structures and comedonecrosis. Neoplastic cells were mildly pleomorphic with an eosinophilic cytoplasm and features 
consistent with apocrine differentiation. Immunohistochemical stainings showed a diffuse positivity for GCDFP15 (c) and androgen receptor 
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CONCLUSION
ree-year delayed metastatic parotid carcinoma of the T11 
vertebral body was adequately managed with separation 
surgery achieved through an extracavitary transpedicular 
partial anterior corpectomy and posterior pedicle screw 
fusion, followed by radiation therapy.
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